Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer
Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Read More
Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma
Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC
Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC